Global Antibacterial Drugs Market Is Expected To Reach USD 5,056.3 Mn By 2022
Posted by johnson on November 6th, 2017
The latest market report published by Credence Research, Inc. “Global Antibacterial Drugs Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022,” the antibacterial drugs market was valued at USD 42,232.2 Mn in 2015, and is expected to reach USD 45,909.4 Mn by 2022, expanding at a CAGR of 1.15% from 2016 to 2022.
Browse the full report Antibacterial Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/antibacterial-drugs-market
Antibacterial drugs are derived from bacteria or molds or are synthesized de novo. These drugs treat infectious diseases caused by gram positive, gram negative, aerobic and anaerobic bacteria that cannot be treated by any other method unlike other diseases. Antibacterial drugs have several mechanisms of action, including inhibiting cell wall synthesis, increasing cell membrane permeability, interfering with protein synthesis, nucleic acid metabolism, and other metabolic processes. The alarming antibacterial-resistance crisis has penetrated the awareness of clinicians, researchers, policymakers, governments and the public at large. The key factors assisting the growth of antibacterial drugs market are mounting prevalence of infectious diseases, government support, and increased research and development activities. However, evolving drug-resistant species, launch of generics, and upcoming patent expirations are anticipated to restrict the growth of the global market through 2022. Globally, the rise in geriatric population is also being considered as one of the key growth factors as it will indirectly increase the demand for various antibacterial drugs. The demand for antibacterial drugs will continue to rise mainly due to increased prevalence of resistant species that demand development of innovative molecules.
The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available antibacterial drugs. Thus, future commercialization of these drugs during the forecast period 2016 – 2022 is anticipated to have a reflective impact on the growth of the overall antibacterial drugs market.
To Know More Download Free Report Sample Here: http://www.credenceresearch.com/sample-request/57891
Key Market Movements:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE,
Like it? Share it!
About the Authorjohnson
Joined: February 23rd, 2017
Articles Posted: 806
More by this author